Observational study shows primaquine's safety for Plasmodium vivax in Ethiopia, suggesting monitoring for adverse events is vital.
In this study, conducted in a population with a low prevalence of G6PD deficiency, a 14-day regimen of low-dose primaquine was well tolerated and resulted in few mild adverse events only. These findings support the current national policy for low-dose primaquine in Ethiopia without prior G6PD testing, if systems for monitoring adverse events are in place.
No takes yet. Share an insight, caveat, or question.
Shifraw et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: